LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Ascendis Pharma A-S ADR

Fermé

SecteurSoins de santé

225.42 -1.55

Résumé

Variation du prix de l'action

24h

Actuel

Min

222.16

Max

225.42

Chiffres clés

By Trading Economics

Revenu

28M

-33M

Ventes

32M

245M

Marge bénéficiaire

-13.56

Employés

1,189

EBITDA

68M

15M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+29.05% upside

Dividendes

By Dow Jones

Prochains Résultats

30 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-288M

13B

Ouverture précédente

226.97

Clôture précédente

225.42

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 févr. 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 févr. 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 févr. 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 févr. 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 févr. 2026, 23:21 UTC

Résultats

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 févr. 2026, 23:20 UTC

Résultats

Nickel Industries 2025 Operating Profit US$126.4 Million

22 févr. 2026, 23:19 UTC

Résultats

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 févr. 2026, 23:19 UTC

Résultats

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 févr. 2026, 23:18 UTC

Résultats

Nickel Industries Won't Pay a Final Dividend

22 févr. 2026, 23:16 UTC

Résultats

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 févr. 2026, 21:35 UTC

Résultats

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 févr. 2026, 21:34 UTC

Résultats

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 févr. 2026, 21:34 UTC

Résultats

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 févr. 2026, 21:33 UTC

Résultats

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 févr. 2026, 21:33 UTC

Résultats

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 févr. 2026, 21:28 UTC

Résultats

Ampol Final Dividend A$0.60/Share

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Revenue A$31.37 Billion, Down 10%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 févr. 2026, 21:28 UTC

Résultats

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 févr. 2026, 14:31 UTC

Acquisitions, Fusions, Rachats

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 févr. 2026, 23:12 UTC

Acquisitions, Fusions, Rachats

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 févr. 2026, 22:12 UTC

Résultats

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 févr. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 févr. 2026, 21:23 UTC

Résultats

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 févr. 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 févr. 2026, 21:01 UTC

Acquisitions, Fusions, Rachats

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 févr. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Comparaison

Variation de prix

Ascendis Pharma A-S ADR prévision

Objectif de Prix

By TipRanks

29.05% hausse

Prévisions sur 12 Mois

Moyen 290.36 USD  29.05%

Haut 342 USD

Bas 250 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

11

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

157.66 / 167.29Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat